Clinipace is ranked #36 in FORBES’ list of America’s 100 Most Promising Companies.

This is truly a great honor and it can be attributed to the dedication and expertise of our employees who work tirelessly to deliver a new service delivery model that is changing and improving the way clinical trials are run through a technology-enabled platform.

In compiling the list, FORBES strove for a holistic gauge of young, privately-held companies, trying to pin down their trajectories by looking at a slew of variables. Over the course of six months, FORBES reviewed thousands of applications. The final assessment is based on growth (both in sales and hiring), quality of management team and investors, margins, market size and key partnerships.

Clinipace now employs over 450 individuals and we have extended our global footprint with the addition of offices in Irvine, California, High Wycombe, United Kingdom, and Trivandrum, India.  We have closed four global acquisitions over the past three years. Most recently, acquiring Paragon Biomedical in September of 2012, expanding our therapeutic expertise, site management capabilities, and clinical operations.

The publication hits newstands on February 13.  In the interim, the online story can be found at